Event Details

Date: March 28, 2026

Location: Reverchon Park and Katy Trail, 3505 Maple Ave, Dallas, Texas

Event Website: https://events.go2.org/dallas2026

Event Overview

Cizzle Bio is proud to serve as a sponsor of the 2026 GO2 Dallas 5K Walk/Run, an annual community event organized by GO2 for Lung Cancer to raise awareness, support patients, and fund critical research.

This family friendly event brings together lung cancer patients, survivors, caregivers, clinicians, and supporters for a day of movement, connection, and purpose. Participants can choose to walk or run the 5K, join as individuals or teams, and take part in activities designed for all ages and abilities.

Held at Reverchon Park and the Katy Trail, the event also features community activities including music and a kid’s dash, creating an engaging and inclusive environment for participants and supporters alike.

Why This Event Matters

• Support lung cancer awareness, early detection, and patient advocacy efforts.

• Help fund programs that provide screening, treatment navigation, and one on one patient support.

• Contribute to advancing research focused on improving outcomes and accelerating cures.

• Join a community working to transform lung cancer from a disease of stigma to one of hope and progress.

Cizzle Bio’s Role as a Sponsor

As a company advancing biomarker blood tests for early cancer detection, Cizzle Bio is proud to support initiatives that directly impact patients and families affected by lung cancer.

Sponsoring the GO2 Dallas 5K Walk/Run reflects our commitment to raising awareness, supporting the lung cancer community, and advancing earlier detection. By partnering with organizations like GO2 for Lung Cancer, we aim to contribute to meaningful progress in research, education, and patient support.

Join the Movement

Whether walking, running, or supporting from the sidelines, this event offers an opportunity to make a meaningful impact. Participation helps fund essential services and brings visibility to the importance of early detection and improved outcomes in lung cancer care.